clozapine Side Effects
Also known as: Clozaril
Analysis of 121,298 adverse event reports submitted to the FDA from 2001 to 2025.
Total Reports
121,298
Death-Related
21,448
17.7% of reports
Hospitalizations
53,005
43.7% of reports
Top Indication
Product Used For Unknown Indication
Most Reported Adverse Reactions
Who Reports Side Effects
Gender Distribution
Age Distribution
Reporting Trend by Year
Reactions in Death Reports
Top reactions reported in 21,448 reports where death was an outcome. These are voluntarily reported and do not establish causation.
| Reaction | Reports |
|---|---|
| DEATH | 11,395 |
| PNEUMONIA | 1,078 |
| COMPLETED SUICIDE | 743 |
| MYOCARDIAL INFARCTION | 736 |
| CARDIAC ARREST | 689 |
| NEUTROPHIL COUNT INCREASED | 599 |
| WHITE BLOOD CELL COUNT INCREASED | 508 |
| TOXICITY TO VARIOUS AGENTS | 499 |
| MALAISE | 478 |
| LUNG NEOPLASM MALIGNANT | 458 |
| OFF LABEL USE | 431 |
| FALL | 428 |
| NEOPLASM MALIGNANT | 426 |
| OVERDOSE | 410 |
| PNEUMONIA ASPIRATION | 391 |
| GENERAL PHYSICAL HEALTH DETERIORATION | 390 |
| SEPSIS | 348 |
| NEUTROPHILIA | 346 |
| CHRONIC OBSTRUCTIVE PULMONARY DISEASE | 338 |
| DYSPNOEA | 330 |
Reactions in Hospitalization Reports
Top reactions in 53,005 reports where hospitalization was an outcome.
| Reaction | Reports |
|---|---|
| HOSPITALISATION | 12,089 |
| SCHIZOPHRENIA | 3,328 |
| MALAISE | 2,582 |
| TREATMENT NONCOMPLIANCE | 2,492 |
| PNEUMONIA | 2,319 |
| NEUTROPENIA | 2,292 |
| PSYCHOTIC DISORDER | 2,213 |
| NEUTROPHIL COUNT INCREASED | 2,178 |
| WHITE BLOOD CELL COUNT INCREASED | 2,169 |
| WHITE BLOOD CELL COUNT DECREASED | 1,978 |
| DRUG INEFFECTIVE | 1,939 |
| OFF LABEL USE | 1,852 |
| FALL | 1,827 |
| MENTAL IMPAIRMENT | 1,676 |
| PYREXIA | 1,674 |
| TACHYCARDIA | 1,507 |
| DRUG INTERACTION | 1,481 |
| CONFUSIONAL STATE | 1,442 |
| NEUTROPHIL COUNT DECREASED | 1,363 |
| CONSTIPATION | 1,336 |
Nearby — Related Medications
What the FAERS Data Reveals About clozapine Side Effects
The FDA Adverse Event Reporting System (FAERS) contains 121,298 voluntary reports linked to clozapine and its brand equivalents (Clozaril), spanning 2001 through 2025. Of those, 21,448 (17.7%) listed death as an outcome and 53,005 (43.7%) involved hospitalization. The most common indication reported alongside adverse events was Product Used For Unknown Indication.
Demographic breakdowns help contextualize who is being exposed to the drug. Of reports with known sex, 39% were female and 61% male; age distribution skews toward 18-44, with 30,098 reports in that bracket. The single most reported reaction is neutropenia with 18,655 submissions, followed by hospitalisation and death.
FAERS is a signal-detection tool, not a scorecard. Reports are voluntary, and a single case may list multiple suspect drugs, so numbers above should not be read as incidence rates or per-patient risk. Widely prescribed drugs naturally accumulate more reports than niche therapies even when individual risk is low. These aggregates are useful for spotting patterns that merit further pharmacovigilance, not for choosing between medications. This page is for educational reference only and is not medical advice — speak with a licensed clinician about any side-effect concerns.
Read our methodology — how this data is sourced, computed, and verified.